Autolus Therapeutics plc (NASDAQ:AUTL) Given Average Rating of "Buy" by Analysts

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) has been assigned an average rating of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have covered the stock in the last year is $9.52.

A number of research analysts recently issued reports on AUTL shares. Wells Fargo & Company cut their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th.

Autolus Therapeutics Stock Down 5.3 %

AUTL traded down $0.09 during trading on Friday, hitting $1.62. The company's stock had a trading volume of 611,867 shares, compared to its average volume of 1,380,174. The business's 50 day simple moving average is $2.01 and its 200-day simple moving average is $2.88. The firm has a market cap of $431.07 million, a PE ratio of -1.34 and a beta of 2.07. Autolus Therapeutics has a one year low of $1.56 and a one year high of $6.60.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. Equities research analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently modified their holdings of AUTL. Virtus ETF Advisers LLC lifted its position in shares of Autolus Therapeutics by 29.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after buying an additional 6,081 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after acquiring an additional 8,479 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock worth $151,000 after acquiring an additional 9,000 shares in the last quarter. State Street Corp grew its holdings in shares of Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company's stock valued at $2,202,000 after purchasing an additional 10,401 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.